Close Menu

NEW YORK (GenomeWeb) – CareFirst Blue Cross Blue Shield and Exosome Diagnostics announced today that they have agreed to collaborate on clinical studies aimed at driving health plan coverage for molecular diagnostic products.

The deal marks the first CareFirst has signed as part of its HealthWorx program under which the payor works with early-stage companies to generate evidence demonstrating the clinical utility of their tests and technologies in order to accelerate the coverage determination process.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
26

As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.